Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region
08. Januar 2025 10:20 ET
|
Research and Markets
Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Central Nervous System Therapeutics Market by Disease, by Drug Class, by Distribution Channel, and by Region" report has been added to ...
Blood Brain Barrier Technologies Market Outlook to 2028 & 2033
13. Dezember 2024 09:11 ET
|
Research and Markets
Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "Blood Brain Barrier Technologies Market 2024" report has been added to ResearchAndMarkets.com's offering.The blood brain barrier technologies market...
Qinotto and Lilly Enter Research Collaboration and License Agreement
08. Oktober 2024 12:00 ET
|
Qinotto Inc
SAN CARLOS, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Qinotto, Inc., a central nervous system (CNS) focused biopharmaceutical company that is discovering novel vehicles to deliver large molecule...
Krabbe Disease Treatment Markets, Companies, and Growth Opportunities 2024-2030 - Advancements in Gene Therapy Expand Addressable Market
11. September 2024 12:39 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "Krabbe Disease Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Krabbe...
Blood Brain Barrier Market Assessment 2024-2035, Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions
11. September 2024 04:09 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration,...
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
05. August 2024 11:00 ET
|
NeOnc Technologies Holdings, Inc.
NeOnc’s second concurrent Phase 2 clinical study seeks further safety and preliminary evidence of biological effects of its lead drug candidate, NEO100™, on certain cancers of the brain and central...
Lewy Body Disease Therapeutics Market Research 2024: Comprehensive Insights about 10+ Companies and 12+ Pipeline Drugs
30. Juli 2024 04:17 ET
|
Research and Markets
Dublin, July 30, 2024 (GLOBE NEWSWIRE) -- The "Lewy Body Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "Lewy Body Disease - Pipeline...
NeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212™, a Patented Novel Hybrid Drug Designed to Deliver ‘Double Punch’ Against Malignant Brain Tumors
24. Juli 2024 11:15 ET
|
NeOnc Technologies Holdings, Inc.
NEO212™ completes initial two cohorts of Phase 1 study under FDA Investigative New Drug (IND).Study tests the safety of NeOnc’s patented novel drug, NEO212™, which is the bioconjugation of its leading...
NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation
16. Juli 2024 11:15 ET
|
NeOnc Technologies Holdings, Inc.
FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1...
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
26. Juni 2024 16:39 ET
|
NeOnc Technologies Holdings, Inc.
New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round.Financing supports further...